Hospital readmission was defined as any unplanned hospitalization. therapy in patients with telomeropathies, though given the design and scope of this study, the actual clinical effect needs further evaluation in larger trials. viremia. Patients were included in our analysis if they survived 3 months post-administration of alemtuzumab. Definitions We assessed for several different outcomes post-administration of alemtuzumab; any complication occurring more than 7 days post- administration of alemtuzumab was included. Outcomes assessed include leukopenia (total WBC 4,000/uL), neutropenia (ANC 1000/uL), lymphocytopenia (ALC 1000/uL), thrombocytopenia (platelets 150,000/uL), need for packed red blood cells (PRBCs), platelets, or granulocyte colony stimulating factor (G-CSF), time to CD4+ lymphocyte recovery ( 200 cells/mL), hospital readmission, infection requiring hospitalization, occurrence of malignancy, CMV viremia ( 137 copies of CMV DNA in serum), EBV viremia ( 2,000 copies DNA) and time to death. At BWH, G-CSF is routinely given if absolute neutrophil counts are 1000 despite adjustment of bone marrow-suppressive medications, regardless of presence of infection. Hospital readmission was defined as any unplanned hospitalization. Infection was defined as any suspected or documented organ dysfunction due to a microorganism that required hospitalization, and Clofazimine for which antimicrobials were prescribed. Statistical Analysis Statistical analysis was performed using STATA version 15. 1 (StatCorp LLC, College Station, TX). For all results, 0.05 were considered significant. Differences in baseline demographic data were assessed using Fisher’s Exact test for binary data. We performed univariate analyses using Fisher’s Exact Clofazimine test to assess for significant differences between alemtuzumab and telomere length Clofazimine for binary outcomes. Results Twenty-two individuals who underwent lung transplantation between 1/1/2012 and 12/31/2018 ultimately received alemtuzumab for either refractory ACR or CLAD. Of those individuals, 2 died within 90 days of alemtuzumab administration and were excluded from your analysis; these individuals did not possess known telomeropathies. Of the remaining 20 individuals, 4 individuals met pre-specified criteria to undergo telomere length screening (see criteria outlined in the Methods section). Three of the four individuals who were tested met criteria for having short telomere lengths, with recorded lymphocyte telomere lengths 10th percentile. Observe Table 1 for further details. The additional 17 individuals did not fulfill our pre-specified criteria to undergo telomere length analysis. Notably, while all three individuals experienced low lymphocyte telomere lengths, patient #1 experienced very low telomere lengths Rabbit Polyclonal to LMO3 in the lymphocyte lineage, with age-matched lengths 1st percentile. Pre-transplant bone marrow biopsy results mirrored the degree of involvement of telomeropathies (Observe Table 1); patient #1 experienced markedly low cellularity, while individuals #2 and #3 experienced moderately reduced cellularity. Table 1 Age-adjusted telomere lengths in various cell lines and bone marrow biopsy results in individuals with short telomeres. = 17)= 0.046), thrombocytopenia (100 vs. 23.5%, = 0.031), and anemia requiring PRBCs (66 vs. 5.9%, = 0.046). There was no significant difference in unplanned hospitalizations, infections necessitating hospitalization, lymphocytopenia, need for G-CSF therapy or CMV or EBV viremia. Moreover, there did not look like numerical variations in post-alemtuzumab survival, though this could not become statistically analyzed (Table 3). There did look like a pattern towards higher response to alemtuzumab in individuals without known telomeropathy, with higher stability of FEV1 over a 6-month period following therapy administration, though the small sample size precludes statistical analysis (Number 1). Table 3 Results in individuals receiving Alemtuzumab. hybridizationG-CSFGranulocyte colony revitalizing factorHSVHerpes simplex virusIQRInterquartile rangeNKNatural Killer. Footnotes Funding. Study in the SE-C Lab is supported by NIH R01-HL130275 and by the John M. Kent Memorial Account..